

REGISTERED OFFICE

GRANULES INDIA LTD., 2nd Floor, 3rd Block, My Home Hub,

Madhapur, Hyderabad – 500 081, Telangana, INDIA.

Tel: +91 40 69043500, Fax: +91 40 23115145, mail@granulesindia.com, www.granulesindia.com

CIN: L24110TG1991PLC012471

Dated September 12, 2024

To,

National Stock Exchange of India Limited

BSE Limited

Symbol: NSE: GRANULES; BSE: 532482

Sub: Update

Ref: Press Release dated September 07, 2024

Dear Sir/Mam,

In reference to our communication dated September 07, 2024 regarding the completion of the USFDA inspection at our Gagillapur FD facility, conducted from 26th August to 6th September 2024, which concluded with six observations.

We acknowledge that several investors have sought clarification, and we want to reassure them that we are actively addressing the observations and are fully committed to resolving the issues raised. We will work with the USFDA to address the issues raised in the observations.

At Granules, quality and compliance are paramount, and these principles are deeply embedded in our ongoing review and governance processes.

The company will continue to provide updates in a timely manner and as appropriate.

This is for your information and dissemination to the members of the exchange.

Thanking You.

Yours sincerely,

For GRANULES INDIA LIMITED

CHAITANYA TUMMALA (COMPANY SECRETARY & COMPLIANCE OFFICER)